# Palvella Announces FDA Priority Review for Qtorin Rapamycin Application

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/42939
Published: 2026-10-28T20:48:38.000Z
Updated: 2026-10-28T20:48:38.000Z
Section: Regulation

> The application seeks U.S. approval for the topical candidate, and Palvella shares traded higher Wednesday.

Palvella Therapeutics, Inc. announced Wednesday that the U.S. Food and Drug Administration granted priority review to its new drug application for Qtorin rapamycin, a topical product candidate seeking U.S. approval.

Qtorin rapamycin is Palvella’s lead product candidate. Shares of Palvella (NASDAQ: PVLA) traded higher Wednesday.